That leads into my second question. Some people who criticize Canada's bringing in of a universal pharmacare system also argue that it will restrict the formulary, that patients will not get access to the drugs they need, and that it will restrict innovation. What was the U.K.'s experience in that regard?
On May 30th, 2016. See this statement in context.